U.S. FDA Approves Dupilumab for the Treatment of BP
Add the treatment of adults with bullous pemphigoid (BP) to the long list of U.S. Food and Drug Administration (FDA) approvals for dupilumab (Dupixent, Sanofi & Regeneron).
Day: June 20, 2025
Add the treatment of adults with bullous pemphigoid (BP) to the long list of U.S. Food and Drug Administration (FDA) approvals for dupilumab (Dupixent, Sanofi & Regeneron).